Price Movement and Market Comparison
On 1 December 2025, Shree Ganesh Biotech India recorded a day change of -4.84%, underperforming its sector by 7.24%. The stock closed at Rs.0.58, establishing a fresh 52-week and all-time low. This price level is notably below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.
Comparing the stock's short-term and long-term performance against the Sensex reveals a stark contrast. Over the past day, the stock declined by 3.23%, while the Sensex gained 0.34%. The one-week performance shows a fall of 7.69% for Shree Ganesh Biotech India, whereas the Sensex advanced by 1.29%. The divergence widens over longer periods: one month sees a decline of 18.92% versus a Sensex gain of 2.45%, and three months show a 21.05% drop against a 7.01% rise in the benchmark index.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Extended Performance Trends
Examining the stock's trajectory over the past year and beyond highlights the severity of its decline. The one-year performance shows a reduction of 43.93%, while the Sensex recorded a gain of 7.76%. Year-to-date figures indicate a 42.31% fall for Shree Ganesh Biotech India, contrasting with a 10.06% rise in the Sensex. Over three years, the stock has fallen by 64.71%, whereas the Sensex appreciated by 35.89%. The five-year comparison is even more pronounced, with the stock down 87.84% against a Sensex increase of 92.58%. Notably, the stock has not recorded any gain over the past decade, remaining flat at 0.00%, while the Sensex surged by 228.62% during the same period.
Financial Health and Profitability Indicators
Shree Ganesh Biotech India's financial metrics reveal ongoing difficulties. The company reported net sales of Rs.5.16 crores for the nine-month period ending September 2025, reflecting a contraction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) for the same period was a loss of Rs.0.61 crores, also showing a decline of 44.64%.
The company's ability to manage its debt obligations appears constrained, with an average EBIT to interest ratio of 0.91, indicating limited earnings relative to interest expenses. Return on equity (ROE) averaged 2.62%, signalling modest profitability relative to shareholders' funds.
Operational efficiency metrics further underscore challenges. The debtors turnover ratio for the half-year period stands at 0.00 times, suggesting difficulties in realising receivables. Additionally, the company has recorded negative earnings before interest, taxes, depreciation, and amortisation (EBITDA), which contributes to the perception of elevated risk in its valuation compared to historical averages.
Shareholding and Market Capitalisation
The majority of Shree Ganesh Biotech India's shares are held by non-institutional investors. The market capitalisation grade assigned to the company is moderate, reflecting its size within the Pharmaceuticals & Biotechnology sector.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Contextualising the Stock’s Position
The persistent downward trend in Shree Ganesh Biotech India's stock price, coupled with its financial indicators, reflects a prolonged period of subdued performance within the Pharmaceuticals & Biotechnology sector. The stock's underperformance relative to the Sensex and its sector peers is evident across multiple time horizons, from daily to decade-long comparisons.
While the company operates in a sector known for innovation and growth potential, its current financial data points to constrained revenue generation and profitability. The negative EBITDA and low return on equity highlight the challenges faced in generating sustainable earnings. Furthermore, the limited ability to service debt obligations adds to the financial pressures.
Market participants observing the stock will note the significant gap between the company’s valuation and its historical averages, underscoring the elevated risk profile. The stock’s position below all major moving averages further emphasises the prevailing bearish sentiment.
Summary of Key Metrics
To summarise, Shree Ganesh Biotech India’s stock price at Rs.0.58 represents an all-time low, with a day decline of 4.84% and underperformance against both sector and benchmark indices. The company’s net sales and profit after tax have contracted by over 44% in the recent nine-month period. Financial ratios such as EBIT to interest and return on equity indicate limited earnings capacity and profitability. The stock’s valuation is considered risky relative to its historical norms, with negative EBITDA and a significant decline in returns over the past year.
These factors collectively illustrate the current state of the company’s market standing and financial health within the Pharmaceuticals & Biotechnology sector.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
